263 related articles for article (PubMed ID: 33329089)
1.
Pearce BD; Massa N; Goldsmith DR; Gandhi ZH; Hankus A; Alrohaibani A; Goel N; Cuthbert B; Fargotstein M; Barr DB; Panuwet P; Brown VM; Duncan E
Front Psychiatry; 2020; 11():552743. PubMed ID: 33329089
[No Abstract] [Full Text] [Related]
2. Toxoplasma gondii exposure affects neural processing speed as measured by acoustic startle latency in schizophrenia and controls.
Pearce BD; Hubbard S; Rivera HN; Wilkins PP; Fisch MC; Hopkins MH; Hasenkamp W; Gross R; Bliwise N; Jones JL; Duncan E
Schizophr Res; 2013 Oct; 150(1):258-61. PubMed ID: 23953218
[TBL] [Abstract][Full Text] [Related]
3. Relationship between Toxoplasma gondii seropositivity and acoustic startle response in an inner-city population.
Massa NM; Duncan E; Jovanovic T; Kerley K; Weng L; Gensler L; Lee SS; Norrholm S; Powers A; Almli LM; Gillespie CF; Ressler K; Pearce BD
Brain Behav Immun; 2017 Mar; 61():176-183. PubMed ID: 27884623
[TBL] [Abstract][Full Text] [Related]
4. Dysregulation of kynurenine pathway and potential dynamic changes of kynurenine in schizophrenia: A systematic review and meta-analysis.
Cao B; Chen Y; Ren Z; Pan Z; McIntyre RS; Wang D
Neurosci Biobehav Rev; 2021 Apr; 123():203-214. PubMed ID: 33513412
[TBL] [Abstract][Full Text] [Related]
5. The effect of antipsychotic medications on acoustic startle latency in schizophrenia.
Fargotstein M; Hasenkamp W; Gross R; Cuthbert B; Green A; Swails L; Lewison B; Boshoven W; Keyes M; Duncan E
Schizophr Res; 2018 Aug; 198():28-35. PubMed ID: 28732798
[TBL] [Abstract][Full Text] [Related]
6. The immune-kynurenine pathway in social anxiety disorder.
Butler MI; Long-Smith C; Moloney GM; Morkl S; O'Mahony SM; Cryan JF; Clarke G; Dinan TG
Brain Behav Immun; 2022 Jan; 99():317-326. PubMed ID: 34758380
[TBL] [Abstract][Full Text] [Related]
7. Polygenic risk scores differentiate schizophrenia patients with toxoplasma gondii compared to toxoplasma seronegative patients.
Lori A; Avramopoulos D; Wang AW; Mulle J; Massa N; Duncan EJ; Powers A; Conneely K; Gillespie CF; Jovanovic T; Ressler KJ; Pearce BD
Compr Psychiatry; 2021 May; 107():152236. PubMed ID: 33721583
[TBL] [Abstract][Full Text] [Related]
8. Association of the kynurenine pathway metabolites with clinical, cognitive features and IL-1β levels in patients with schizophrenia spectrum disorder and their siblings.
Noyan H; Erdağ E; Tüzün E; Yaylım İ; Küçükhüseyin Ö; Hakan MT; Gülöksüz S; Rutten BPF; Saka MC; Atbaşoğlu C; Alptekin K; van Os J; Üçok A
Schizophr Res; 2021 Mar; 229():27-37. PubMed ID: 33609988
[TBL] [Abstract][Full Text] [Related]
9. Kynurenine pathway metabolites are associated with gray matter volume in subjects with schizophrenia.
Zhou S; Huang Y; Kuang Q; Yan S; Li H; Wu K; Wu F; Huang X
Front Psychiatry; 2022; 13():941479. PubMed ID: 36016974
[TBL] [Abstract][Full Text] [Related]
10. Relationship of prolonged acoustic startle latency to diagnosis and biotype in the bipolar-schizophrenia network on intermediate phenotypes (B-SNIP) cohort.
Massa N; Owens AV; Harmon W; Bhattacharya A; Ivleva EI; Keedy S; Sweeney JA; Pearlson GD; Keshavan MS; Tamminga CA; Clementz BA; Duncan E
Schizophr Res; 2020 Feb; 216():357-366. PubMed ID: 31796306
[TBL] [Abstract][Full Text] [Related]
11. Cross-sectional relationship between kynurenine pathway metabolites and cognitive function in major depressive disorder.
Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Ning Y
Psychoneuroendocrinology; 2019 Mar; 101():72-79. PubMed ID: 30419374
[TBL] [Abstract][Full Text] [Related]
12. Increased breakdown of kynurenine towards its neurotoxic branch in bipolar disorder.
Birner A; Platzer M; Bengesser SA; Dalkner N; Fellendorf FT; Queissner R; Pilz R; Rauch P; Maget A; Hamm C; Herzog-Eberhard S; Mangge H; Fuchs D; Moll N; Zelzer S; Schütze G; Schwarz M; Reininghaus B; Kapfhammer HP; Reininghaus EZ
PLoS One; 2017; 12(2):e0172699. PubMed ID: 28241062
[TBL] [Abstract][Full Text] [Related]
13. Preliminary comparative analysis of kynurenine pathway metabolites in chronic ketamine users, schizophrenic patients, and healthy controls.
Zhang Z; Zhang M; Luo Y; Ni X; Lu H; Wen Y; Fan N
Hum Psychopharmacol; 2020 Jul; 35(4):e2738. PubMed ID: 32352599
[TBL] [Abstract][Full Text] [Related]
14. Early Life Stress and the Fate of Kynurenine Pathway Metabolites.
Coplan JD; George R; Syed SA; Rozenboym AV; Tang JE; Fulton SL; Perera TD
Front Hum Neurosci; 2021; 15():636144. PubMed ID: 33994977
[TBL] [Abstract][Full Text] [Related]
15. Hypercoagulability is independently associated with kynurenine pathway activation in dialysed uraemic patients.
Pawlak K; Mysliwiec M; Pawlak D
Thromb Haemost; 2009 Jul; 102(1):49-55. PubMed ID: 19572067
[TBL] [Abstract][Full Text] [Related]
16. Combined Toxoplasma gondii seropositivity and high blood kynurenine--Linked with nonfatal suicidal self-directed violence in patients with schizophrenia.
Okusaga O; Duncan E; Langenberg P; Brundin L; Fuchs D; Groer MW; Giegling I; Stearns-Yoder KA; Hartmann AM; Konte B; Friedl M; Brenner LA; Lowry CA; Rujescu D; Postolache TT
J Psychiatr Res; 2016 Jan; 72():74-81. PubMed ID: 26594873
[TBL] [Abstract][Full Text] [Related]
17. Altered kynurenine pathway metabolites in serum of chronic migraine patients.
Curto M; Lionetto L; Negro A; Capi M; Fazio F; Giamberardino MA; Simmaco M; Nicoletti F; Martelletti P
J Headache Pain; 2015; 17():47. PubMed ID: 27130315
[TBL] [Abstract][Full Text] [Related]
18. The impact of electroconvulsive therapy on the tryptophan-kynurenine metabolic pathway.
Guloksuz S; Arts B; Walter S; Drukker M; Rodriguez L; Myint AM; Schwarz MJ; Ponds R; van Os J; Kenis G; Rutten BP
Brain Behav Immun; 2015 Aug; 48():48-52. PubMed ID: 25765557
[TBL] [Abstract][Full Text] [Related]
19. Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression.
Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Li M; Ning Y
Brain Behav Immun; 2018 Nov; 74():205-212. PubMed ID: 30213652
[TBL] [Abstract][Full Text] [Related]
20. The association between inflammation and kynurenine pathway metabolites in electroconvulsive therapy for schizophrenia: Implications for clinical efficacy.
Wang Y; Fang X; Wang G; Tang W; Liu S; Yang Y; Chen J; Ling Y; Zhou C; Zhang X; Zhang C; Su KP
Brain Behav Immun; 2023 Oct; 113():1-11. PubMed ID: 37353059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
